How Gilead Stabilized the HIV Combination Pill Truvada
A patent detailing a stable, fixed-dose combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent chemical breakdown in a single tablet.
Original patent title: “Compositions and methods for combination antiviral therapy”
A patent detailing a stable, fixed-dose combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent chemical breakdown in a single tablet. Granted to Gilead Sciences Inc in 2017 with 32 claims.
Key facts
Coverage
What does this patent actually cover?
This patent describes a specific pharmaceutical formulation that combines two potent antiviral drugs, tenofovir disoproxil fumarate (TDF) and emtricitabine, into a single, stable tablet. A major challenge in combining these drugs is that they can chemically react with each other or degrade when exposed to heat and humidity, rendering the medication ineffective. The patent specifies a precise mixture of excipients—inactive substances like pregelatinized starch, croscarmellose sodium, and lactose monohydrate—that act as a protective matrix. By maintaining these specific ratios and using a desiccant during storage, the tablet achieves a high level of chemical stability, ensuring less than 5% degradation even after six months in harsh conditions.
The gap
What does this patent NOT cover?
- Does not cover the individual chemical compounds tenofovir disoproxil fumarate or emtricitabine themselves.
- Does not cover liquid formulations or other non-tablet delivery methods for these drugs.
- Does not cover combinations that do not meet the specific stability threshold of less than 5% degradation under the stated temperature and humidity conditions.
- Does not cover generic combinations that use different excipients or ratios outside of the specific formulations claimed.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
What made this novel
The innovation lies in the precise selection of excipients that prevent the two active ingredients from interacting chemically, effectively 'locking' them in a stable state within the tablet matrix.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Truvada
Atripla (which includes a third agent, efavirenz)
Why it matters
The bigger picture
This technology is the backbone of Truvada, a landmark medication for both HIV treatment and pre-exposure prophylaxis (PrEP). By combining two drugs into one pill, it significantly improved patient adherence to treatment regimens, which is critical for suppressing the virus and preventing transmission. The stability of this formulation allowed for global distribution of a reliable, once-daily therapy.
Filed
October 24, 2014
Granted
August 29, 2017
Market context
Who's building on this
Companies in this space
Gilead Sciences remains the primary entity associated with this formulation. Many generic pharmaceutical manufacturers have since developed their own versions of this combination, often navigating the patent landscape to provide lower-cost alternatives once the core patents expired.
Market impact
This patent helped solidify the dominance of single-tablet regimens in HIV care, shifting the standard of care from complex multi-pill routines to simplified daily dosing. It became a cornerstone of Gilead's HIV franchise, enabling the company to maintain a significant market position while drastically improving the quality of life for patients worldwide.
Claim 1 — Plain English
What this patent covers
This patent describes a specific pharmaceutical formulation that combines two potent antiviral drugs, tenofovir disoproxil fumarate (TDF) and emtricitabine, into a single, stable tablet. A major challenge in combining these drugs is that they can chemically react with each other or degrade when exposed to heat and humidity, rendering the medication ineffective. The patent specifies a precise mixture of excipients—inactive substances like pregelatinized starch, croscarmellose sodium, and lactose monohydrate—that act as a protective matrix. By maintaining these specific ratios and using a desiccant during storage, the tablet achieves a high level of chemical stability, ensuring less than 5% degradation even after six months in harsh conditions.
The clever bit
The innovation lies in the precise selection of excipients that prevent the two active ingredients from interacting chemically, effectively 'locking' them in a stable state within the tablet matrix.
What it does not cover
- Does not cover the individual chemical compounds tenofovir disoproxil fumarate or emtricitabine themselves.
- Does not cover liquid formulations or other non-tablet delivery methods for these drugs.
- Does not cover combinations that do not meet the specific stability threshold of less than 5% degradation under the stated temperature and humidity conditions.
- Does not cover generic combinations that use different excipients or ratios outside of the specific formulations claimed.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
20/20
Very broad protection
Recency
10/20
Granted 5–10 years ago
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$90K – $288K
Midpoint $180K · 8.4 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
The original legal language
Original claims
32 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Oliyai, R., Dahl, T. C., & Menning, M. M. (2017). How Gilead Stabilized the HIV Combination Pill Truvada (U.S. Patent No. 9,744,181). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/9744181/harvoni-ledipasvir-sofosbuvir
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US9744181"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How Gilead Stabilized the HIV Combination Pill Truvada cover?
A patent detailing a stable, fixed-dose combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent chemical breakdown in a single tablet.
Who owns patent US 9744181?
Gilead Sciences Inc owns this patent, granted in 2017.
When does this patent expire?
This patent is expected to expire on August 29, 2037, when the invention enters the public domain.
What problem does this patent solve?
This technology is the backbone of Truvada, a landmark medication for both HIV treatment and pre-exposure prophylaxis (PrEP). By combining two drugs into one pill, it significantly improved patient adherence to treatment regimens, which is critical for suppressing the virus and preventing transmission. The stability of this formulation allowed for global distribution of a reliable, once-daily therapy.
What does this patent NOT cover?
Does not cover the individual chemical compounds tenofovir disoproxil fumarate or emtricitabine themselves.
Same assignee
More from Gilead Sciences Inc
Patent monitoring